pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Oxaliplatin
drug
save

Entia

Marketedupdated 6mo ago
by Teva Pharmaceuticals USA Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval16 co-mentions · 8 sources
  • drugXalox9 co-mentions · 9 sources
  • drugOXALIPLATIN9 co-mentions · 9 sources
  • tagOncology2 co-mentions · 1 sources
  • drugFLUOROURACIL1 co-mentions · 1 sources
  • drugEfudex1 co-mentions · 1 sources
  • drugFAVLYXA1 co-mentions · 1 sources
  • companyTehran University of Medical Sciences1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Entia

  • phase3Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)completedn=738
  • phase2A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumorsrecruitingn=392
  • phase3RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinomanot yet recruitingn=680
  • phase2Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)recruitingn=160
  • phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studiesrecruitingn=170
  • phase3A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancerrecruitingn=500
  • phase1A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumorsrecruitingn=260
  • phase2Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinomanot yet recruitingn=34

News(2)

  • An ADC specialist sinks on safety concerns for blood cancer drug
    Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
    biopharma_dive · 5mo ago
  • Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
    Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.
    onclive · 6mo ago
brand
Oxaliplatin
generic
oxaliplatin
indication
Colon Cancer
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?